BC
ICPT

BHR Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

BHR Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-12,000
Closed -$2.9M – 46
2015
Q2 		$2.9M Buy
+12,000
New +$3.2M 0.38% 34

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

BHR Capital's ICPT Position: Q3 2015 in Review

BHR Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2015, closing a stake of 12,000 shares — an estimated $2.9M sold.

BHR Capital first reported a position in ICPT in Q2 2015 and held it in 1 quarter. The position peaked at $2.9M in Q2 2015. 173 funds tracked by Wall St. Rank hold ICPT as of Q3 2015.

  • BHR Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • BHR Capital sold 12,000 Intercept Pharmaceuticals, Inc. shares in Q3 2015, an estimated $2.9M.
  • BHR Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • BHR Capital's Intercept Pharmaceuticals, Inc. position peaked at $2.9M in Q2 2015.
  • 173 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2015.

Based on BHR Capital's 13F filing for Q3 2015, filed 16 Nov 2015.